Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment publishing date : 2021 - 11 - 01 save search
Global Ion Exchange Resins Markets, 2021-2026 - Water-Guzzling Industrial Units and Increasing Emphasis on Sustainable Wastewater Treatment Benefit Demand
Published: 2021-11-01 (Crawled : 22:00) - prnewswire.com
BIO | $290.86 -0.65% -0.16% 190K
|
Health Technology
|
| O: 0.75%
H: 0.74%
C: -1.39%
treatment ema trial
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
Published: 2021-11-01 (Crawled : 20:00) - biospace.com/
AUPH | $4.91 -1.8% -1.83% 1.1M
|
Health Technology
|
| O: -3.26%
H: 4.59%
C: 1.97%
treatment lupkynis results lupus
Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
COCP | $1.44 -1.37% -1.39% 8.4K
|
Health Technology
|
| O: 3.12%
H: 3.26%
C: 2.72%
covid new drug treatment fda drug
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
THRX | $4.06 0.49% 0
|
|
| O: 1.05%
H: 2.6%
C: -0.98%
new drug fda clearance treatment fda application test gastrointestinal drug clearance
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0672 178.69% 100
|
Health Technology
|
| O: -4.6%
H: 5.49%
C: 4.83%
treatment
Insights on the Non-Melanoma Skin Cancer Treatment Global Market to 2026 - by Treatment Type, Indication, End-use and Region
Published: 2021-11-01 (Crawled : 18:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: -0.17%
H: 1.58%
C: 0.65%
ICAD | $1.57 -1.88% -1.91% 87K
|
Technology Services
|
| O: 0.0%
H: 0.85%
C: -0.57%
ARAY | News | $2.205 -1.12% -1.13% 460K
|
Health Technology
|
| O: 0.0%
H: 8.82%
C: 7.01%
treatment skin cancer cancer skin
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published: 2021-11-01 (Crawled : 15:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
NVS | News | $93.08 -0.13% 0.86% 1.2M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: 0.0%
treatment fda myeloid leukemia leukemia fda approval
Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
SRNE | $0.0275 -8.85% 53K
|
Health Technology
|
| O: -0.15%
H: 5.26%
C: 2.92%
treatment cancer antibody license
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
MIRM | $23.87 -0.58% -0.59% 330K
|
Health Technology
|
| O: -0.19%
H: 4.45%
C: 2.4%
treatment syndros lancet
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
MBIO | $0.373 7.74% 7.18% 440K
|
Health Technology
|
| O: 0.45%
H: 6.22%
C: 5.78%
FBIO | $1.79 1.7% 1.68% 240K
|
Health Technology
|
| O: -0.61%
H: 6.17%
C: 6.17%
treatment therapy car-t t-cell
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.15 0.0% 1.3M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.15 0.0% 1.3M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance granted
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.